ABRYL LABORATORIES PRIVATE LIMITED – FDA 483, Sep 26, 2025
Abryl Laboratories Private Limited, a sterile drug manufacturer in District S.A.S. Nagar (Mohali), India, was cited for significant deficiencies across its aseptic and sterilization processes. The inspection revealed inadequate validation of critical manufacturing steps, poor environmental monitoring, and insufficient laboratory controls. Repeat observations highlighted persistent issues with discrepancy investigations and computer system controls, indicating systemic quality control failures.
ID · de803bfe-4f89-45c2-a530-9fd457dd5870
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.